Literature DB >> 21557732

Constitutive formation of an RXFP1-signalosome: a novel paradigm in GPCR function and regulation.

Michelle L Halls1.   

Abstract

The classical second messenger cAMP is important in diverse physiological processes, where its spatial and temporal compartmentalization allows precise control over multiple cellular events. Within this context, G-protein-coupled receptors (GPCRs) govern specialized pools of cAMP, which are functionally specific for the unique cellular effects attributed to a particular system. The relaxin receptor, RXFP1, is a GPCR that exerts pleiotropic physiological effects including a potent anti-fibrotic response, increased cancer metastases, and has efficacy as a vasodilator in heart failure. On a cellular level, relaxin stimulation of RXFP1 results in the activation of multiple G-protein pathways affecting cAMP accumulation. Specificity and diversity in the cAMP signal generated by RXFP1 is controlled by differential G-protein coupling dependent upon the background of cellular expression, and cAMP compartmentalization. Further complexity in cAMP signalling results from the constitutive assembly of an RXFP1-signalosome, which specifically responds to low concentrations of relaxin, and activates a distinct cAMP pathway. The RXFP1-signalosome is a higher-order protein complex that facilitates receptor sensitivity to attomolar concentration of peptide, exhibits constitutive activity and dual coupling to G-proteins and β-arrestins and reveals a concentration-biased agonism mediated by relaxin. The specific and directed formation of GPCR-centered signalosomes allows an even greater spatial and temporal control of cAMP, thus rationalizing the considerable physiological scope of this ubiquitous second messenger.
© 2011 The Author. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21557732      PMCID: PMC3372819          DOI: 10.1111/j.1476-5381.2011.01470.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  146 in total

Review 1.  Emerging role of relaxin in renal and cardiovascular function.

Authors:  Kirk P Conrad; Jacqueline Novak
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2004-08       Impact factor: 3.619

Review 2.  Relaxin's physiological roles and other diverse actions.

Authors:  O David Sherwood
Journal:  Endocr Rev       Date:  2004-04       Impact factor: 19.871

3.  Dynamic regulation of cAMP synthesis through anchored PKA-adenylyl cyclase V/VI complexes.

Authors:  Andrea L Bauman; Joseph Soughayer; Bao T Nguyen; Debbie Willoughby; Graeme K Carnegie; Wei Wong; Naoto Hoshi; Lorene K Langeberg; Dermot M F Cooper; Carmen W Dessauer; John D Scott
Journal:  Mol Cell       Date:  2006-09-15       Impact factor: 17.970

4.  Relaxin enhances the oncogenic potential of human thyroid carcinoma cells.

Authors:  Sabine Hombach-Klonisch; Joanna Bialek; Bogusz Trojanowicz; Ekkehard Weber; Hans-Jürgen Holzhausen; Josh D Silvertown; Alastair J Summerlee; Henning Dralle; Cuong Hoang-Vu; Thomas Klonisch
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

5.  Relaxin family peptide receptors RXFP1 and RXFP2 modulate cAMP signaling by distinct mechanisms.

Authors:  Michelle L Halls; Ross A D Bathgate; Roger J Summers
Journal:  Mol Pharmacol       Date:  2006-03-28       Impact factor: 4.436

6.  Increased expression of the relaxin receptor (LGR7) in human endometrium during the secretory phase of the menstrual cycle.

Authors:  Courtney P Bond; Laura J Parry; Chrishan S Samuel; Helen M Gehring; Fiona L Lederman; Peter A W Rogers; Roger J Summers
Journal:  J Clin Endocrinol Metab       Date:  2004-07       Impact factor: 5.958

7.  Relaxin down-regulates renal fibroblast function and promotes matrix remodelling in vitro.

Authors:  Rosemary Masterson; Tim D Hewitson; Kristen Kelynack; Marina Martic; Laura Parry; Ross Bathgate; Ian Darby; Gavin Becker
Journal:  Nephrol Dial Transplant       Date:  2004-03       Impact factor: 5.992

8.  Protein associated with Myc (PAM) is involved in spinal nociceptive processing.

Authors:  Corina Ehnert; Irmgard Tegeder; Sandra Pierre; Kerstin Birod; Hong-Van Nguyen; Achim Schmidtko; Gerd Geisslinger; Klaus Scholich
Journal:  J Neurochem       Date:  2004-02       Impact factor: 5.372

9.  Phosphodiesterase 4 inhibition synergizes with relaxin signaling to promote decidualization of human endometrial stromal cells.

Authors:  Olaf Bartsch; Bettina Bartlick; Richard Ivell
Journal:  J Clin Endocrinol Metab       Date:  2004-01       Impact factor: 5.958

10.  Identification of relaxin-3/INSL7 as an endogenous ligand for the orphan G-protein-coupled receptor GPCR135.

Authors:  Changlu Liu; Elo Eriste; Steven Sutton; Jingcai Chen; Barbara Roland; Chester Kuei; Niven Farmer; Hans Jörnvall; Rannar Sillard; Timothy W Lovenberg
Journal:  J Biol Chem       Date:  2003-09-30       Impact factor: 5.157

View more
  8 in total

1.  Themed section: molecular pharmacology of GPCRs.

Authors:  R J Summers
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  The chemokine receptor CCR1 is constitutively active, which leads to G protein-independent, β-arrestin-mediated internalization.

Authors:  C Taylor Gilliland; Catherina L Salanga; Tetsuya Kawamura; JoAnn Trejo; Tracy M Handel
Journal:  J Biol Chem       Date:  2013-09-20       Impact factor: 5.157

Review 3.  Heart Disease and Relaxin: New Actions for an Old Hormone.

Authors:  Teja Devarakonda; Fadi N Salloum
Journal:  Trends Endocrinol Metab       Date:  2018-03-08       Impact factor: 12.015

Review 4.  Synthetic non-peptide low molecular weight agonists of the relaxin receptor 1.

Authors:  Alexander I Agoulnik; Irina U Agoulnik; Xin Hu; Juan Marugan
Journal:  Br J Pharmacol       Date:  2016-11-30       Impact factor: 8.739

5.  Differential effects of the Gβ5-RGS7 complex on muscarinic M3 receptor-induced Ca2+ influx and release.

Authors:  Darla Karpinsky-Semper; Claude-Henry Volmar; Shaun P Brothers; Vladlen Z Slepak
Journal:  Mol Pharmacol       Date:  2014-02-28       Impact factor: 4.436

Review 6.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

7.  RNA SEQ Analysis Indicates that the AE3 Cl-/HCO3- Exchanger Contributes to Active Transport-Mediated CO2 Disposal in Heart.

Authors:  Kanimozhi Vairamani; Hong-Sheng Wang; Mario Medvedovic; John N Lorenz; Gary E Shull
Journal:  Sci Rep       Date:  2017-08-04       Impact factor: 4.379

8.  Cardioprotection Achieved Through Overexpression of Relaxin Receptors.

Authors:  Xiao-Jun Du
Journal:  JACC Basic Transl Sci       Date:  2022-01-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.